Aldesleukin causes release of cytokines that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates and potential serious adverse reactions.
Source: NLP:aldesleukin
Cyp Substrates Interactions
2 interactions on record
Epcoritamab-bysp causes cytokine release that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates. This is more likely after the first dose and up to 14 days after the first 48 mg dose, and during/after CRS.
Source: NLP:epcoritamab-bysp